Safety of a non-adjuvanted therapeutic vaccine for the treatment of feline dermatophytosis

The safety of a non-adjuvanted inactivated fungal vaccine for the treatment of dermatophytosis in cats was investigated in two studies: a controlled laboratory study, and a placebo-controlled double-blind field study with a cross-over design in Europe. In the laboratory study, two groups of 10 cats each were administered an intramuscular twofold overdose, followed by five single 1 ml doses, of either vaccine or control product at 14-day intervals. In the field study, cats were treated with three intramuscular injections of 1 ml vaccine administered at 14-day intervals, as recommended by the manufacturer. A total of 89 cats were enrolled in the field study and divided into two groups to receive either vaccine or placebo for the first three treatments, followed by the opposite product for the final three treatments. The cats enrolled in the two studies were 12 weeks of age or older, as recommended by the manufacturer. All the cats were monitored closely for possible injection site reactions, systemic reactions (including changes in rectal body temperature) and adverse events. The results from both studies showed no significant differences between the vaccinated cats and the control or placebo-treated cats with regard to local or systemic reactions. A few mild to moderate local reactions were noted, but these were evenly distributed between the vaccinated and placebo-treated cats and resolved within a few days. No severe or serious adverse events related to the vaccinations were observed.     

Preventive and therapeutic efficacy of the vaccine against trychophytosis in cattle]

The effectiveness of vaccine against dermatomycosis, caused by Trichophyton verrucosum, was studied in young cattle in three herds. The vaccines of Czechoslovak and Soviet production had almost the same effectiveness in prevention. In healthy calves without clinical signs of trichophytosis vaccinated at an age of one to three months with a dose of 2.5 to 5.0 ml, applied intramuscularly, and revaccinated with due respect to the rules of hygiene in the calf-houses, an incidence of 0 to 13% in the three- to five-month period of study was observed. In the non-vaccinated control groups, the incidence under the same infection conditions and in the same period was 36.3 to 100.0%. At the early stage of vaccination--during the inoculation of the animals suspected of being infected--the incidence of the disease was 50.0 to 68.8% and mostly showed no difference from incidence observed in the nonvaccinated control cattle. The therapeutic effect of the vaccine and Mykolastanox F is characterized by the fact that zero prevalence was obtained in the animals ten weeks after vaccination. Animals treated locally with Mykolastanox F showed zero prevalence 12 weeks after the beginning of treatment.     

猪口蹄疫○型合成肽疫苗诱导的免疫抗体的监测

设3组猪群,首免和二免分别注射生理盐水1 mL、猪口蹄疫0型合成肽疫苗1 mL(说明书推荐免疫剂量)及猪口蹄疫0型合成肽疫苗3 mL(说明书推荐免疫剂量3倍量),二免28天后检测猪群的口蹄疫抗体,结果显示3组猪群的抗体合格率分别为33%、78%和100%,疫苗诱导的抗体水平达到农业部规定的动物强制免疫标准。     

Surveillance on the immune antibodies against synthetic peptide vaccine for 0 type FMDV

设3组猪群,首免和二免分别注射生理盐水1mL、猪口蹄疫0型合成肽疫苗1mL（说明书推荐免疫剂量）及猪口蹄疫0型合成肽疫苗3mL（说明书推荐免疫剂量3倍量）,二免28天后检测猪群的13＇蹄疫抗体,结果显示3组猪群的抗体合格率分别为33％、78％和100％,疫苗诱导的抗体水平达到农业部规定的动物强制免疫标准。     

Recombinant S3Pvac-phage anticysticercosis vaccine: Simultaneous protection against cysticercosis and hydatid disease in rural pigs

This paper provides macroscopic and histological evidence on the statistically significant protective effects of S3Pvac-phage vaccination against porcine cysticercosis and hydatidosis. The study included 391 rustically bred pigs (187 vaccinated and 204 controls). Vaccination significantly reduced the prevalence of cysticercosis by 61.7%. Vaccination also significantly reduced by 56.1% the prevalence of hydatidosis caused by Echinococcus granulosus in pigs. The presence of the vaccine epitopes in both cestodes is probably involved in the cross-protection observed. Increased inflammation was found in 5% of cysticerci recovered from controls, versus 24% from vaccinated pigs (P<0.01). Hydatid cysts were non-inflammatory in either group. Vaccination was effective to prevent one single disease, but it failed to prevent the simultaneous infections with both parasites in a same pig. The widening of the S3Pvac-phage vaccine protective repertoire to include hydatidosis is a convenient feature that should reduce the prevalence of two frequent zoonoses that affect rustic porcine breading with a single action. Thus, the costs of two different vaccination programs would be reduced to a single one with significant reduction in both zoonoses.     

A field trial to assess the therapeutic and prophylactic effect of a foot rot vaccine in sheep

An 18-week field trial was conducted on a sheep ranch to evaluate the therapeutic and prophylactic effect of a commercial foot rot vaccine. Two hundred sheep were included in the study, 100 with detectable foot rot lesions and 100 without. Approximately 50 sheep from each group were selected randomly and vaccinated twice against foot rot at a 6-week interval in the late spring 1984; the remaining sheep acted as nonvaccinated controls. Therapeutic effect of the vaccine was demonstrated by a cure rate of 53% in vaccinated, foot rot-affected sheep vs a cure rate of 19% in nonvaccinated, foot rot-affected sheep. Prophylactic effect of the vaccine was demonstrated by a foot rot prevalence at the end of the 18-week period of 9% for vaccinated sheep vs 53% for nonvaccinated sheep. Associations of foot rot lesions and vaccination with body condition were found to be significant, as was the association between foot rot lesions and mortality.     

Use of biodegradable PLGA microspheres as a slow release delivery system for the Boophilus microplus synthetic vaccine SBm7462

The synthetic anti-Boophilus microplus vaccine SBm7462 derived from the tick intestinal protein, Bm86, induced a protective immune response when emulsified in saponin and used in cattle. Using a mice model, and with the objective of improving the vaccine by continual peptide release, it was encapsulated in PLGA 50:50 microspheres and inoculated in BALB/c mice to assess the immunological response by detection of anti-peptide IgGs. Comparative studies were made with the peptide emulsified in saponin and with another synthetic vaccine, and the microsphere/peptide was characterized for efficiency of encapsulation, in vitro release profile, morphology, size, peptide integrity after encapsulation and stability in different pHs. The findings showed that saponin enhances a better immune response from SBm7462 and that the PLGA 50:50 microspheres are suitable for use with this peptide.     

Testing for immunogenic and protective properties of vaccine against tissue-inactivated rabies

The immunogenic and protective potency was tested of vaccine against inactivated tissue rabies developed from the Vnukovo-32 strain, and produced in the Bioveta state corporation at Ivanovice in Haná. In 21 days after an i. m. application of 3 cm3 of vaccine, the average titre of virus-neutralizing antibodies was found to be 1:47. In this period the animals were revaccinated in the same way. The average titre of virus-neutralizing antibodies was 1:99 three months after revaccination, 1:57 in six months and 1:24 in nine months. In this period a challenge test was performed in a dog using the dose of 10(5) MICLD50 of street rabies virus. This dose was implanted i. m. into masticatory muscles. Another dog was infected experimentally 18 months after immunization. The experiment has proved the good immunogenic potency of vaccine against inactivated tissue rabies and its ability to induce the protection of vaccinated dogs from the strees infection with street rabies virus. The control rabies vaccine of foreign make RABISIN was tested in a similar way.